Preclinical efficacy of anecortave acetate.
Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.
Clark
Abbot F
AF
Discovery Research, Alcon Research, Ltd. Ft. Worth, Texas 76134, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D011244:Pregnadienediols / Q000627:therapeutic use*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D011244:Pregnadienediols; C418047:anecortave acetate